Overview
U.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior year
In January 2026, company received $13 mln international order for oral TPOXX
Outlook
SIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026
Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026
SIGA focused on securing new procurement contracts with governments to support future revenues
Result Drivers
U.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. government
DEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025
Company press release: ID:nGNX3WGZVj
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS | $0.32 | ||
FY Net Income | $23.3 mln |
Analyst Coverage
The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)